Mounjaro (tirzepatide) is a brand-name drug prescribed to treat type 2 diabetes in adults. Mounjaro comes as a solution inside injection pens that you’ll administer weekly as a subcutaneous ...

Today we've published final guidance for the weight loss medication tirzepatide (mounjaro). It means the phased roll out – set out in our guidance – will begin in 2025. In 2022, the government ...

"Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect a continuation of that trend into 2025. We'll also bring additional manufacturing capacity online and expect to produce ...

The U.S. incretin market includes: Mounjaro, Zepbound, Trulicity, semaglutide and liraglutide. Top investment firms expect non-US stocks to outperform. Here are Morningstar’s top international ...

"Sales of Mounjaro and Zepbound posted robust sales growth in Q4, and we expect a continuation of that trend into 2025. We'll also bring additional manufacturing capacity online and expect to ...

The U.S. incretin market includes: Mounjaro, Zepbound, Trulicity, semaglutide and liraglutide. The Dyrt, the only camping app with all of the public, private and free camping locations in the ...

The clear laggard has been Trulicity, a diabetes/weight loss drug that has been cannibalized by the surge in sales for Mounjaro and Zepbound. In Q3, Trulicity sales tumbled by 22% to $1.30 bln. The ...

2024 revenue is expected to be approximately $45.0 billion for the full year, $4.0 billion above the midpoint of first-time 2024 financial guidance The company anticipates 2025 revenue to be in ...

the company expressly disclaims any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this release. The U.S. incretin market includes: ...

News reports have warned about the Santa Ana winds and their power to turn modest wildfires into conflagrations. Here’s why these wind patterns can be so destructive. The Santa Ana winds (named ...